Colorectal Cancer (CRC) Active Not Recruiting Phase 1 Trials for Nivolumab (DB09035)

Back to Colorectal Cancer (CRC)

Also known as: Malignant Neoplasm of Colorectum / CRC, Colorectal Cancer / Colorectal Cancer / Cancer, Colorectal / CRC (Colorectal Cancer) / Colorectal, Cancer / Colo-rectal Cancer / Colorectal Cancers / A. Colorectal Cancer / Cancer Colorectal / Gastrointestinal Cancers - Colorectal / CRC / CRCS / Malignant colorectal neoplasm / Malignant neoplasm of cecum and/or colon and/or rectum / Malignant neoplasm of caecum and/or colon and/or rectum / Malignant neoplasm of cecum and/or colon and/or rectum (disorder) / Malignant neoplasm of large intestine / Malignant tumor of large intestine / Malignant tumour of large intestine / Malignant neoplasm of large intestine (disorder) / Malignant neoplasm of colon, unspecified / Malignant large intestinal neoplasm NOS / Cancer of large intestine / Malignant neoplasm of large intestine, NOS / Cancer of large bowel / CA - Cancer of large bowel / Colorectal neoplasms malignant / Malignant neoplasm of colon and/or rectum (disorder) / Large intestine carcinoma / Colorectal carcinoma / Colorectal cancer NOS

Indication	Status	Phase
DBCOND0031867 (Colorectal Cancer (CRC))	Active Not Recruiting	1

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT04017650	Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer	Treatment	Cetuximab (DB00002) Encorafenib (DB11718) Nivolumab (DB09035)
NCT06540261	The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer	Treatment	Bevacizumab (DB00112) Cetuximab (DB00002) Fluorouracil (DB00544) Levoleucovorin (DB11596) Magrolimab (DB16225) Nivolumab (DB09035) Oxaliplatin (DB00526)
NCT06547385	Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer	Treatment	Bevacizumab (DB00112) Capecitabine (DB01101) Fluorouracil (DB00544) Leucovorin (DB00650) Nivolumab (DB09035) ONO-4578 (DB22389) Oxaliplatin (DB00526)
NCT05704985	Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors	Treatment	Capecitabine (DB01101) Carboplatin (DB00958) DK210 (DB24308) Fluorouracil (DB00544) Nivolumab (DB09035) Oxaliplatin (DB00526) Paclitaxel (DB01229) Pembrolizumab (DB09037)
NCT04117087	Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer	Treatment	Hiltonol (DB17293) Ipilimumab (DB06186) Nivolumab (DB09035)
NCT03872947	A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors	Treatment	Bevacizumab (DB00112) Carboplatin (DB00958) Cisplatin (DB00515) Fluorouracil (DB00544) Gemcitabine (DB00441) Imiquimod (DB00724) Irinotecan (DB00762) Leucovorin (DB00650) Nivolumab (DB09035) Paclitaxel (DB01229) Pegylated doxorubicin (DB32018) Pembrolizumab (DB09037) Ramucirumab (DB05578) TRK-950 (DB22441)